News
Montelukast: UK regulator says asthma drug needs clearer warnings of side effects
BMJ 2024; 385 doi: https://doi.org/10.1136/bmj.q1048 (Published 08 May 2024) Cite this as: BMJ 2024;385:q1048- Gareth Iacobucci
- The BMJ
The asthma drug montelukast (Singulair) will carry more prominent warnings in the UK to alert doctors and patients to its potentially serious behavioural and neuropsychiatric side effects.
Previously noted side effects associated with the oral treatment include sleep disturbances, depression, and agitation (which may affect up to one in 100 people); disturbances of attention or memory (up to one in 1000); and hallucinations and suicidal …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.